Comparison of PET/CT using 68Ga-NOTA-Exendin-4 with 68Ga-DOTATATE, 18F-FDG, and conventional imaging in the localization of insulinomas.
Haonan Yu, Xiangyuan Bao, Yian Gu...
https://pubmed.ncbi.nlm.nih.gov/40259061/Actively Recruiting
Led by Tianjin Medical University · Updated on 2026-09-08
500
Participants Needed
3
Research Sites
N/A
Total Duration
This research aims to evaluate the usefulness of 68Ga18F-Exendin 4 positron emission tomographycomputed tomography PETCT scans for diagnosing primary and metastatic lesions in patients with various GLP-1 receptor-related diseases. It involves patients who may have suspected, newly diagnosed, or previously treated malignant tumors related to GLP-1R. The study focuses on measuring how well this imaging technique detects these lesions. Participants receive a single intravenous injection of 68Ga18F-Exendin 4 and then undergo PETCT imaging within a specified timeframe. The study analyzes the uptake of the tracer in lesions by calculating the maximum standardized uptake value SUVmax. It assesses diagnostic accuracy by measuring sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy. During the study, participants undergo the PETCT scan and related assessments. Researchers collect imaging data to evaluate the tracer uptake and diagnostic efficacy within 30 days. Participants provide informed consent before enrollment. The primary outcome measure is the standardized uptake value, with diagnostic efficacy as a secondary measure. The study includes adults aged 18 to 80 and monitors safety and imaging results throughout the study period.
CONDITIONS
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Q
Qiusong Chen, MD
H
Haonan Yu, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tianjin Medical University
Lead Sponsor
Tianjin Medical University General Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days
Participants receive a single intravenous injection of 68Ga/18F-Exendin 4 and undergo PET/CT imaging within a specified time to detect lesions.
1 visit (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Haonan Yu, Xiangyuan Bao, Yian Gu...
https://pubmed.ncbi.nlm.nih.gov/40259061/Tianjin Medical University
Lead Sponsor
Tianjin Medical University General Hospital
Collaborating Sponsor